

Amendments to the Specification:

Please amend the paragraph starting at page 1, line 23 as follows:

In one subset of the nutraceutical compositions, the fourth herb is *Centipeda ~~minimal~~ minima* (L.) A. Br. Et Aschers (e.g., its whole plant, "E-Bu-Shi-Cao" in Chinese). They include those wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5). As indicated by this weight ratio, the first herb may not be included. In other words, the nutraceutical compositions may contain extracts of only three herbs.

Please amend the paragraph starting at page 2, line 18 as follows:

The compositions used in the method of treating such a disorder include those wherein the fourth herb is *Centipeda ~~minimal~~ minima* (L.) A. Br. Et Aschers (whole plant) or *Magnolia biondii* Pamp. (flower); those wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5); and those containing extracts of three or four herbs.

Please amend the paragraph starting at page 3, line 1 as follows:

Accordingly, a nutraceutical composition of this invention includes extracts of the root of *Hedysarum polybotrys* Hand.-Mazz. or *Astragalus membranaceus* Bge., the root of *Atractylodes macrocephala* kodiz., the root of *Ledebouriella seseloides* (hoffm.) Wolff, and at least a fourth herb which is an anti-allergy herb. Examples of the fourth herb include, but are not limited to, the whole plant of *Centipeda ~~minimal~~ minima* (L.) A. Br. Et Aschers and the flower of *Magnolia biondii* Pamp., *Magnolia denudata* Desr., *Magnolia sprengeri*, or *Magnolia liliflora* Desr. The weight ratio of the extracts of the first, second, third, and fourth herbs can be in the range of (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5). Preferred ratios can be determined by efficacy-evaluating methods described below or analogous methods. The nutraceutical composition is unexpectedly effective for the treatment of disorders related to excessive secretion of histamine or interleukin-4, such as allergic rhinitis, asthma, and eczema.

Applicant : Ching-Hsiang Hsu
Serial No. : 10/645,054
Filed : August 21, 2003
Page : 3 of 9

Attorney's Docket No.: 12841-006001

Please amend the paragraph starting at page 5, line 13 as follows:

Two tested nutraceutical compositions of this invention, which contained extracts of the whole plant of *Centipeda ~~minimal~~ minima* (L.) A. Br. Et Aschers and the flower of *Magnolia biondii* Pamp. as the fourth herb, respectively, proved to be efficacious in treating allergic rhinitis.